Tempus AI Stock Surges as Merck-Moderna Cancer Trial Validates Personalis Acquisition

Tempus AI Inc shares surged Wednesday morning, with traders linking the rally to a landmark clinical trial victory and the company's recent billion-dollar acquisition. Here's what investors need to know.

Tempus AI stock hit new highs Wednesday. What's driving the TEM surge?

Landmark mRNA Trial Delivers Breakthrough Results

The rally stems from Phase III trial results released Wednesday morning by Merck & Co Inc and Moderna Inc. The two pharma partners announced that their INTerpath-001 trial, evaluating intismeran autogene, showed significant improvement in recurrence-free survival in patients with resected melanoma.

The news marks the first successful Phase III trial result for a customized mRNA-based cancer treatment.

Key Link: Personalis Infrastructure Powers Vaccine Development

While Merck and Moderna lead drug development, the engine driving the personalized vaccine is Personalis Inc's advanced genomic tumor analysis technology. Moderna uses Personalis' sequencing platform to analyze each patient's unique tumor tissue and identify the specific neoantigens needed to manufacture customized doses.

This technological connection directly benefits Tempus AI, which previously partnered with Personalis to commercialize minimal residual disease detection and agreed last month to acquire Personalis for $1.5 billion.

Through the Personalis acquisition, Tempus gained critical sequencing infrastructure supporting Moderna's treatment program, which just cleared its biggest regulatory and clinical milestone to date.

Tempus CEO Eric Lefkofsky highlighted the connection on social media Wednesday, congratulating Moderna and Merck on the Phase III win while noting Tempus' pride in partnering with Moderna to support the breakthrough program.

Congratulations to @moderna_tx and @Merck on today's positive Phase III INTerpath-001 results—a major milestone for melanoma treatment and the future of personalized medicine.

We're proud to support this important program with Moderna, and we're excited to see what's next...

— Eric Lefkofsky, August 19, 2026

TEM Stock Climbs Wednesday Morning

TEM price action: As of Wednesday's data, Tempus AI shares were up 17.77% to $58.13.